Skip to main content
. 2018 Oct 19;9(82):35327–35342. doi: 10.18632/oncotarget.26239

Table 1. Sequences of primers used.

Primers Sequences
AR Forward GACTTCACCGCACCTGATG
Reverse AATGGGCAAAACATGGTCCC
AR-v7 Forward TGTCCATCTTGTCGTCTTCGG
Reverse TGCAATTGCCAACCCGGAAT
ARv567es Forward TTGTACACGTGGTCAAGTGGG
Reverse TGAACTGATGCAGCTCTCTCG
PSA Forward GTCCCGGTTGTCTTCCTCAC
Reverse CTCCCACAATCCGAGACAGG
XPO1 Forward ACGAGGAAGGAAGGAGCAGT
Reverse CGAGCTGCATGGTCTGCTAA
FOXA1 Forward ACCAGCGACTGGAACAGCTA
Reverse GTCATGTTGCCGCTCGTAGT
MED1 Forward GCTTGTGCGTCAAGTCATGG
Reverse TGAGATGAGAGCCCAGTCCA
Src Forward TGTTCGGAGGCTTCAACTCC
Reverse TGTGTTGTTGACAATCTGGAGC
Vav3 Forward GGACTCGGCTCAGGTGTTCG
Reverse GCCCGGAGGTTGTTAAGCAG
Sam68 Forward TGAGAGACAAAGCCAAGGAGG
Reverse CTCACATGGGGGTCCAAAGA
UBE2C Forward TCCTGTCTCTCTGCCAACGC
Reverse TTGTCTGATTCAGGGAAGGCA
actin Forward GCACAGAGCCTCGCCTT
Reverse TCATCATCCATGGTGAGCTG
18 S Forward GCAATTATTCCCCATGAACG
Reverse GGCCTCACTAAACCATCCAA